BackgroundCheck.run
Search For

Darren D Davis, 42Gary, IN

Known as:
Darren Darren Darren D Daivs
Related to:
Darrell Simon Portee 59

Darren Davis Phones & Addresses

Gary, IN   

Homewood, IL   

Cypress, TX   

Houston, TX   

Lafayette, IN   

Get Report
Control this profile

Mentions for Darren D Davis

Career records & work history

License Records

Darren W. Davis

Licenses:
License #: PST.014653 - Active
Issued Date: Mar 16, 1990
Expiration Date: Dec 31, 2017
Type: Pharmacist

Darren Davis resumes & CV records

Resumes

Darren Davis Photo 48

Darren Davis - Daly City, CA

Work:
World Market Nov 2013 to 2000
Stocker CLP Aug 2013 to 2000
Laborer Alliance processors - Houston, TX Oct 2012 to Jul 2013
Lead Driver Alpha tect - Houston, TX Sep 2012 to Jan 2013
Cleaning Technician Grocery supply - Houston, TX Oct 2011 to Jul 2012
Forklift Operator McDonalds - Houston, TX Mar 2005 to Feb 2007
Cook/Customer Service
Education:
1st forklift services - San Francisco Bay Area, CA 2013 to 2013
Forklift certification in Forklift operation Wyndham - Austin, TX 2008 to 2011
Journeyman Carpenter in Construction carpentry Texas Southern university - Houston, TX 2006 to 2007
Some college in Business admin Milby High School - Houston, TX 2002 to 2006
Diploma
Skills:
Computers,Microsoft office,
Darren Davis Photo 49

Darren Davis - La Porte, TX

Work:
Pasadena isd Jun 2014 to 2000
Apprentice Maintenance Chem Spray inc Jun 2012 to May 2013
Herbicide Sprayer apple one - Channelview, TX Apr 2012 to May 2012
Inventory Clerk A & L Industrial Services Mar 2012 to Apr 2012
Laborer Coastal Spray - Pasadena, TX Sep 2009 to Jan 2012
Herbicide Sprayer
Education:
San Jacinto College Central - Pasadena, TX Jul 2013
vocational in Chrysler Automotive Program La Porte High School - La Porte, TX
High School Diploma in Transportation

Publications & IP owners

Us Patents

Evaluating Rtk Target Drugs

US Patent:
2010011, May 6, 2010
Filed:
Mar 7, 2008
Appl. No.:
12/532396
Inventors:
Darren W. Davis - Houston TX, US
Assignee:
Apocell, Inc - Houston TX
International Classification:
C12Q 1/48
G06F 17/30
C12Q 1/02
US Classification:
435 15, 707802, 435 29, 707748, 707E17044
Abstract:
Methods of evaluating receptor tyrosine kinase drug efficacy are demonstrated. The methods generally relate to evaluation methods using phospho-RTK over total RTK ratio (pRTK/tRTK). An algorithm is provided that allows the user to combine the pRTK/tRTK ratios from several kinase together with other kinds of measurements to obtain a PDX value that is indicative of drug efficacy.

C-Kit Phosphorylation In Cancer

US Patent:
2010014, Jun 10, 2010
Filed:
Dec 3, 2007
Appl. No.:
12/517182
Inventors:
Darren W. Davis - Houston TX, US
Assignee:
Apocell, Inc. - Houston TX
International Classification:
G01N 33/53
C07K 16/00
US Classification:
435 71, 5303879, 5303881, 5303873
Abstract:
An antibody is disclosed for the detection of phosphorylated c-KIT. A method of diagnosing and monitoring cancers responsive to treatment using an anti-phospho-c-KIT antibody are also disclosed. A diagnostic kit is also provided for the detection and monitoring of cancers responsive to tyrosine phosphorylation inhibitor treatment.

Systems And Methods For Isolating Target Particles And Their Use In Diagnostic, Prognostic, And Therapeutic Methods

US Patent:
2018023, Aug 16, 2018
Filed:
Aug 9, 2016
Appl. No.:
15/752196
Inventors:
- Houston TX, US
Darren W. Davis - Houston TX, US
International Classification:
G01N 33/574
C12Q 1/6886
B03C 5/00
Abstract:
The present disclosure relates to an apparatus and methods for enriching and analyzing viable target particles of interest from a heterogeneous suspension containing target particles and non-target particles where the particles may be biological or non-biological. The method allows for the resulting target particles or a subset of target particles to undergo further analyses since the particles are not modified or labeled, which would typically interfere with further characterization. Another embodiment may be directed to a method of analyzing a fluid specimen from a subject suffering from a disease or condition comprising the steps of: obtaining a fluid specimen from a subject, culture, or animal model, where the fluid specimen comprises target cells of interest and non-target cells; adding said fluid specimen into a flow chamber; enriching viable target cells from non-target cells of the fluid specimen; and analyzing the viable target cells.

Method For Predicting And Evaluating Responsiveness To Cancer Treatment With Dna-Damaging Chemotherapeutic Agents

US Patent:
2018009, Apr 5, 2018
Filed:
Dec 7, 2017
Appl. No.:
15/835072
Inventors:
- San Francisco CA, US
Christine Taylor Brew - Pacifica CA, US
Stephen David Harrison - Albany CA, US
Dennis G. Fry - Pacifica CA, US
Darren W. Davis - Houston TX, US
International Classification:
G01N 33/573
G01N 33/574
G01N 33/68
Abstract:
Provided herein are methods directed to the prediction and early assessment of the efficacy of cancer treatment regimens, in particular in patients undergoing therapy with a DNA-damaging chemotherapeutic agent, by determining expression levels of certain proteins found to be useful as biomarkers in circulating tumor cells obtained from the patient both prior to and post-treatment.

Possible Relatives

Cynthia O Davis  David R Davis  A Davis  D R Davis  Davina L Davis  Davon L Davis  Davonne Davis  Darren Johnson  Darren L Johnston  Darren M White 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.